Literature DB >> 12724735

Cancer revoked: oncogenes as therapeutic targets.

Dean W Felsher1.   

Abstract

Recent findings show that even the brief inactivation of a single oncogene might be sufficient to result in the sustained loss of a neoplastic phenotype. It is therefore possible that the targeted inactivation of oncogenes could be a specific and effective treatment for cancer. So why does oncogene inactivation cause tumour regression and will this be a generally successful approach for the treatment of human neoplasia?

Entities:  

Mesh:

Year:  2003        PMID: 12724735     DOI: 10.1038/nrc1070

Source DB:  PubMed          Journal:  Nat Rev Cancer        ISSN: 1474-175X            Impact factor:   60.716


  86 in total

1.  MYC Inactivation Elicits Oncogene Addiction through Both Tumor Cell-Intrinsic and Host-Dependent Mechanisms.

Authors:  Dean W Felsher
Journal:  Genes Cancer       Date:  2010-06

2.  CD4(+) T cells contribute to the remodeling of the microenvironment required for sustained tumor regression upon oncogene inactivation.

Authors:  Kavya Rakhra; Pavan Bachireddy; Tahera Zabuawala; Robert Zeiser; Liwen Xu; Andrew Kopelman; Alice C Fan; Qiwei Yang; Lior Braunstein; Erika Crosby; Sandra Ryeom; Dean W Felsher
Journal:  Cancer Cell       Date:  2010-10-28       Impact factor: 31.743

3.  Genomic and proteomic analysis reveals a threshold level of MYC required for tumor maintenance.

Authors:  Catherine M Shachaf; Andrew J Gentles; Sailaja Elchuri; Debashis Sahoo; Yoav Soen; Orr Sharpe; Omar D Perez; Maria Chang; Dennis Mitchel; William H Robinson; David Dill; Garry P Nolan; Sylvia K Plevritis; Dean W Felsher
Journal:  Cancer Res       Date:  2008-07-01       Impact factor: 12.701

Review 4.  An essential role for the immune system in the mechanism of tumor regression following targeted oncogene inactivation.

Authors:  Stephanie C Casey; Yulin Li; Dean W Felsher
Journal:  Immunol Res       Date:  2014-05       Impact factor: 2.829

5.  Optical clearing agent increases effectiveness of photodynamic therapy in a mouse model of cutaneous melanoma: an analysis by Raman microspectroscopy.

Authors:  Letícia Palombo Martinelli; Ievgeniia Iermak; Lilian Tan Moriyama; Michelle Barreto Requena; Layla Pires; Cristina Kurachi
Journal:  Biomed Opt Express       Date:  2020-10-19       Impact factor: 3.732

6.  Pre-clinical compartmental pharmacokinetic modeling of 2-[1-hexyloxyethyl]-2-devinyl pyropheophorbide-a (HPPH) as a photosensitizer in rat plasma by validated HPLC method.

Authors:  Kowthavarapu Venkata Krishna; Ranendra Narayana Saha; Anu Puri; Mathias Viard; Bruce A Shapiro; Sunil Kumar Dubey
Journal:  Photochem Photobiol Sci       Date:  2019-05-15       Impact factor: 3.982

7.  Transducer of erbB2.1 is a potential cellular target of gefitinib in lung cancer therapy.

Authors:  Ke-Kang Sun; Yang Yang; Lin Zhao; Li-Li Wang; Yang Jiao
Journal:  Oncol Lett       Date:  2012-10-15       Impact factor: 2.967

8.  Use of avian retroviral vectors to introduce transcriptional regulators into mammalian cells for analyses of tumor maintenance.

Authors:  William Pao; David S Klimstra; Galen H Fisher; Harold E Varmus
Journal:  Proc Natl Acad Sci U S A       Date:  2003-07-11       Impact factor: 11.205

Review 9.  SGF29 and Sry pathway in hepatocarcinogenesis.

Authors:  Nobuya Kurabe; Shigekazu Murakami; Fumio Tashiro
Journal:  World J Biol Chem       Date:  2015-08-26

10.  Hepatitis B virus X protein upregulates expression of SMYD3 and C-MYC in HepG2 cells.

Authors:  Lian Yang; Jun He; Libo Chen; Guobin Wang
Journal:  Med Oncol       Date:  2008-12-13       Impact factor: 3.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.